Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher G. Levins is active.

Publication


Featured researches published by Christopher G. Levins.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Lipid-like materials for low-dose, in vivo gene silencing

Kevin Love; Kerry P. Mahon; Christopher G. Levins; Kathryn A. Whitehead; William Querbes; J. Robert Dorkin; June Qin; William Cantley; Liu Liang Qin; Timothy Racie; Maria Frank-Kamenetsky; Ka Ning Yip; Rene Alvarez; Dinah Sah; Antonin de Fougerolles; Kevin Fitzgerald; Victor Koteliansky; Akin Akinc; Robert Langer; Daniel G. Anderson

Significant effort has been applied to discover and develop vehicles which can guide small interfering RNAs (siRNA) through the many barriers guarding the interior of target cells. While studies have demonstrated the potential of gene silencing in vivo, improvements in delivery efficacy are required to fulfill the broadest potential of RNA interference therapeutics. Through the combinatorial synthesis and screening of a different class of materials, a formulation has been identified that enables siRNA-directed liver gene silencing in mice at doses below 0.01 mg/kg. This formulation was also shown to specifically inhibit expression of five hepatic genes simultaneously, after a single injection. The potential of this formulation was further validated in nonhuman primates, where high levels of knockdown of the clinically relevant gene transthyretin was observed at doses as low as 0.03 mg/kg. To our knowledge, this formulation facilitates gene silencing at orders-of-magnitude lower doses than required by any previously described siRNA liver delivery system.


Journal of Internal Medicine | 2010

Lipid-based nanotherapeutics for siRNA delivery

Avi Schroeder; Christopher G. Levins; C. Cortez; Robert Langer; Daniel G. Anderson

RNA interference (RNAi) is a specific gene‐silencing mechanism triggered by small interfering RNA (siRNA). The application of RNAi in the clinic requires the development of safe and effective delivery systems. Inspired by progress with lipid‐based systems in drug delivery, efforts have been dedicated to the development of liposomal siRNA delivery systems. Many of the lipid‐based delivery vehicles self‐assemble with siRNA through electrostatic interactions with charged amines, generating multi‐lamellar lipoplexes with positively charged lipid bilayers separated from one another by sheets of negatively charged siRNA strands. Internalization of lipid‐based siRNA delivery systems into cells typically occurs through endocytosis; accordingly, delivery requires materials that can facilitate endosomal escape. The size of the carrier is important as carriers <100 nm in diameter have been reported to have higher accumulation levels in tumours, hepatocytes and inflamed tissue, whereas larger particles tend to be taken up by Kupffer cells or other components of the reticuloendothelial system (RES). To reduce RES uptake and increase circulation time, carriers have been modified on the surface with hydrophilic materials, such as polyethyleneglycol. Herein, we review the molecular and structural parameters of lipid‐based siRNA delivery systems.


Nature Nanotechnology | 2014

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

James E. Dahlman; Carmen Barnes; Omar F. Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E. Shaw; Yiping Xing; Hendrik B. Sager; Gaurav Sahay; Andrew Bader; Roman L. Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet Singh Sandhu; Matthew J. Webber; Tatiana Novobrantseva; Vera M. Ruda; Abigail K. R. Lytton-Jean; Christopher G. Levins; Brian T. Kalish; Dayna K. Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse

Dysfunctional endothelium contributes to more diseases than any other tissue in the body. Small interfering RNAs (siRNAs) can help in the study and treatment of endothelial cells in vivo by durably silencing multiple genes simultaneously, but efficient siRNA delivery has so far remained challenging. Here, we show that polymeric nanoparticles made of low-molecular-weight polyamines and lipids can deliver siRNA to endothelial cells with high efficiency, thereby facilitating the simultaneous silencing of multiple endothelial genes in vivo. Unlike lipid or lipid-like nanoparticles, this formulation does not significantly reduce gene expression in hepatocytes or immune cells even at the dosage necessary for endothelial gene silencing. These nanoparticles mediate the most durable non-liver silencing reported so far and facilitate the delivery of siRNAs that modify endothelial function in mouse models of vascular permeability, emphysema, primary tumour growth and metastasis.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery

Daniel J. Siegwart; Kathryn A. Whitehead; Lutz Nuhn; Gaurav Sahay; Hao Cheng; Shan Jiang; Minglin Ma; Abigail K. R. Lytton-Jean; Arturo Vegas; Patrick Fenton; Christopher G. Levins; Kevin Love; Haeshin Lee; Christina Cortez; Sean P. Collins; Ying Fei Li; Janice Jang; William Querbes; Christopher Zurenko; Tatiana Novobrantseva; Robert Langer; Daniel G. Anderson

Analogous to an assembly line, we employed a modular design for the high-throughput study of 1,536 structurally distinct nanoparticles with cationic cores and variable shells. This enabled elucidation of complexation, internalization, and delivery trends that could only be learned through evaluation of a large library. Using robotic automation, epoxide-functionalized block polymers were combinatorially cross-linked with a diverse library of amines, followed by measurement of molecular weight, diameter, RNA complexation, cellular internalization, and in vitro siRNA and pDNA delivery. Analysis revealed structure-function relationships and beneficial design guidelines, including a higher reactive block weight fraction, stoichiometric equivalence between epoxides and amines, and thin hydrophilic shells. Cross-linkers optimally possessed tertiary dimethylamine or piperazine groups and potential buffering capacity. Covalent cholesterol attachment allowed for transfection in vivo to liver hepatocytes in mice. The ability to tune the chemical nature of the core and shell may afford utility of these materials in additional applications.


Journal of Controlled Release | 2012

Alkane-modified short polyethyleneimine for siRNA delivery.

Avi Schroeder; James E. Dahlman; Gaurav Sahay; Kevin Love; Shan Jiang; Ahmed A. Eltoukhy; Christopher G. Levins; Yingxia Wang; Daniel G. Anderson

RNA interference (RNAi) is a highly specific gene-silencing mechanism triggered by small interfering RNA (siRNA). Effective intracellular delivery requires the development of potent siRNA carriers. Here, we describe the synthesis and screening of a series of siRNA delivery materials. Short polyethyleneimine (PEI, Mw 600) was selected as a cationic backbone to which lipid tails were conjugated at various levels of saturation. In solution these polymer-lipid hybrids self-assemble to form nanoparticles capable of complexing siRNA. The complexes silence genes specifically and with low cytotoxicity. The efficiency of gene knockdown increased as the number of lipid tails conjugated to the PEI backbone increased. This is explained by reducing the binding affinity between the siRNA strands to the complex, thereby enabling siRNA release after cellular internalization. These results highlight the importance of complexation strength when designing siRNA delivery materials.


Archive | 2009

Aminoalcohol lipidoids and uses thereof

Kerry P. Mahon; Kevin Love; Christopher G. Levins; Kathryn A. Whitehead; Robert Langer; Daniel G. Anderson


Archive | 2012

Conjugated lipomers and uses thereof

James E. Dahlman; Avraham D. Schroeder; Daniel G. Anderson; Robert Langer; Christopher G. Levins


Archive | 2011

POLYMERS FOR BIOMATERIALS AND THERAPEUTICS

Omar Z. Fisher; Christopher G. Levins; Robert S. Langer; Daniel G. Anderson


PMC | 2012

Remotely Activated Protein-Producing Nanoparticles

Avi Schroeder; Michael Goldberg; Christian J. Kastrup; Yingxia Wang; Shan Jiang; Brian J. Joseph; Christopher G. Levins; Sneha T. Kannan; Robert Langer; Daniel G. Anderson


Archive | 2012

Lipomères conjugués et utilisations associées

James E. Dahlman; Avraham D. Schroeder; Daniel G. Anderson; Robert S. Langer; Christopher G. Levins

Collaboration


Dive into the Christopher G. Levins's collaboration.

Top Co-Authors

Avatar

Daniel G. Anderson

Lankenau Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

Kevin Love

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Robert Langer

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

James E. Dahlman

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shan Jiang

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Gaurav Sahay

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Kerry P. Mahon

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Avraham D. Schroeder

Massachusetts Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge